Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vascular Solutions takes thrombus tech to Japan

This article was originally published in Clinica

Executive Summary

Vascular Solutions is to start selling in Japan its Pronto catheter, a device that uses mechanical aspiration to remove acute thrombus from the arterial system. The Minneapolis, Minnesota firm said it had received notification from its Japanese distributor Nihon Kohden that the import licence and reimbursement notification for the product's sale in Japan had been completed. "After the US...Japan is the second largest market for thrombus aspiration catheters," said Howard Root, Vascular Solutions' CEO. "Removal of acute thrombus is a potential $100m annual worldwide market opportunity that we are only beginning to realise with the Pronto as it enters its second year of commercial launch and expanding worldwide markets." Clinica FILED 1 June 2005 COPYRIGHT T&F Informa UK Ltd 2005

You may also be interested in...



BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.

STRENGTH Results May Weaken Chances For Omega-3 Fatty Acid Heart Health Claims

Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.

FDA To Combo Product Sponsors: Consider Traditional Pathways Before Asking For Meeting

In a final guidance from the US agency, regulators say most combination product questions are best resolved through traditional pathways and noted that initiating a so-called combination product agreement meeting may be unproductive.

Topics

UsernamePublicRestriction

Register

ID1132679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel